Human Genome Sciences is touting mid-stage data that shows its lupus treatment significantly reducing disease activity. LymphoStat-B reduced disease activity after 52 weeks of therapy and more than 95 percent of the patients in the trial signed on for a new study of the therapy. Investigators will now focus on patients response rates as a primary endpoint in Phase III.
- check out this release on the data
- read the AP report